Liz Barrett | BiotechTV

top of page

BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer

She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple...

Company News

Jun 16

UroGen CEO Liz Barrett shares highlights of the recent Phase 3 ENVISION trial readout in bladder cancer

She describes how patients might benefit from UroGen's gel based technology that keeps chemotherapy locally in the bladder vs having...

Company News

Jun 25, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer

UroGen CEO Liz Barrett shares highlights of the recent Phase 3 ENVISION trial readout in bladder cancer

Follow BiotechTV

Sponsors

Sponsor Spotlight